Premium
Cis‐diamminedichloroplatinum (II): Second line induction chemotherapy in advanced ovarian adenocarcinoma
Author(s) -
Piver M. Steven,
Barlow Joseph J.,
Lele Shashikant B.,
Malfetano John H.,
McPhee Mary Eileen
Publication year - 1983
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930240418
Subject(s) - medicine , cisplatin , chemotherapy , induction chemotherapy , oncology , adenocarcinoma , surgery , cancer
Twenty‐one evaluable patients received second‐line chemotherapy for recurrent ovarian adenocarcinoma with induction Cisplatin given weekly followed by monthly combination chemotherapy. Forty‐two percent of the patients responded to induction weekly Cisplatin. Of the responders, 77% are alive as compared to only 8% of the nonresponders. Maintenance of the responses by monthly combination chemotherapy remains a significant problem. Moreover, 83% and 70% of patients who received weekly Cisplatin as first‐ and third‐line induction chemotherapy, respectively, had objective responses. Of the total 43 patients who received weekly Cisplatin as first‐, second‐, or third‐line chemotherapy, 60% responded, including complete clinical responses in 14% and partial responses in 46%.